Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

被引：0
|
作者：
Chen, Robert W. [1 ]
Gopal, Ajay K. [2 ]
Smith, Scott E. [3 ]
Ansell, Stephen M. [4 ]
Rosenblatt, Joseph D. [5 ]
Savage, Kerry J. [6 ]
Connors, Joseph M. [7 ]
Engert, Andreas [8 ]
Larsen, Emily K. [9 ]
Sievers, Eric L. [9 ]
Younes, Anas [10 ]
机构：
[1] City Hope Natl Med Ctr, Hematol & HCT, Duarte, CA 91010 USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Med Ctr, Seattle, WA 98195 USA
[3] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[4] Mayo Clin, Div Hematol, Rochester, MN USA
[5] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[6] BC Canc Agcy Ctr Lymphoid Canc, Dept Med Oncol, Vancouver, BC, Canada
[7] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada
[8] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[9] Seattle Genet Inc, Bothell, WA USA
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3689.3689
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3689
引用
收藏
页数：2
相关论文
共 50 条
  • [1] LONG-TERM FOLLOW-UP RESULTS OF AN ONGOING PIVOTAL STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL)
    Smith, S.
    Chen, R.
    Gopal, A.
    Ansell, S.
    Rosenblatt, J.
    Savage, K.
    Connors, J.
    Engert, A.
    Larsen, E.
    Sievers, E.
    Younes, A.
    HAEMATOLOGICA, 2012, 97 : 456 - 456
  • [2] Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
    Pro, Barbara
    Advani, Ranjana H.
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey V.
    Ramchandren, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Yang, Yin
    Kennedy, Dana A.
    Shustov, Andrei R.
    BLOOD, 2012, 120 (21)
  • [3] Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis
    Wang, Z.
    Sun, K.
    Zhu, Z-M
    Zhang, P.
    Yang, J.
    Yang, S-W
    Zheng, M-Q
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (07) : 2941 - 2948
  • [4] Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma
    Zsuzsa, Molnar
    Imre, Pinczes Laszlo
    Klara, Piukovics
    Ildiko, Istenes
    Krisztina, Wolf
    Zoltan, Csukly
    Arpad, Szomor
    Arpad, Illes
    Zsofia, Miltenyi
    ORVOSI HETILAP, 2017, 158 (41) : 1630 - 1634
  • [5] Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Palmer, Joycelynne M.
    Herrera, Alex Francisco
    Armenian, Saro H.
    Mei, Matthew
    Popplewell, Leslie
    Fueger, Abbey
    Qasim, Imran
    Stiller, Tracy
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2017, 130
  • [6] Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
    Gopal, Ajay K.
    Chen, Robert
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Chi, Xuedong
    Sievers, Eric L.
    Younes, Anas
    BLOOD, 2015, 125 (08) : 1236 - 1243
  • [7] Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma
    Chen, Runzhe
    Chen, Baoan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1729 - 1733
  • [8] Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
    Zinzani, Pier Luigi
    Derenzini, Enrico
    Pellegrini, Cinzia
    Celli, Monica
    Broccoli, Alessandro
    Argnani, Lisa
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (05) : 681 - 683
  • [9] Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
    Younes, Anas
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Ramchandren, Radhakrishnan
    Bartlett, Nancy L.
    Cheson, Bruce D.
    de Vos, Sven
    Forero-Torres, Andres
    Moskowitz, Craig H.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Kennedy, Dana A.
    Sievers, Eric L.
    Chen, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2183 - 2189
  • [10] Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma
    Zinzani, Pier Luigi
    Gandolfi, Letizia
    Casadei, Beatrice
    Pellegrini, Cinzia
    Broccoli, Alessandro
    Derenzini, Enrico
    Quirini, Federica
    Tonialini, Lorenzo
    Cavo, Michele
    Argnani, Lisa
    Stefoni, Vittorio
    BLOOD, 2015, 126 (23)
12345